Preliminary exploration of clinical factors affecting acute toxicity and quality of life after carbon ion therapy for pr
- PDF / 851,566 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 43 Downloads / 179 Views
RESEARCH
Open Access
Preliminary exploration of clinical factors affecting acute toxicity and quality of life after carbon ion therapy for prostate cancer Yafang Zhang1,3, Ping Li2,3, Qi Yu4, Shuang Wu1,3, Xue Chen1,3, Qing Zhang2,3* and Shen Fu1,3,5,6*
Abstract Purpose: To assess toxicity and quality-of-life (QOL) after carbon ion radiotherapy (CIRT) at the Shanghai Proton and Heavy Ion Center (SPHIC) and identify clinical factors that correlate with urinary, bowel and sexual function. Methods: Sixty-four patients with localized prostate cancer admitted from July 2015 to January 2018 underwent CIRT. At baseline and 5 time-points after radiotherapy, we assessed patients’ QOL using the 26-item edition of the Expanded Prostate Cancer Index-Composite (EPIC-26) Chinese version. Logistic regression was performed to identify clinical factors associated with acute genitourinary (GU) toxicity and relative QOL. Results: By the end of CIRT, urinary irritation/obstruction temporarily declined (− 7.92 ± 1.76, p < .001). For urinary incontinence, bowel and sexual QOL, the scores remained stable at 2-year follow-up. The occurrences of acute Grade 1 and 2 GU toxicity were 20.3 and 10.9%, respectively, and of late Grade 1 and 2 GU toxicity were 3.1 and 1.6%, respectively. No acute or late gastrointestinal (GI) toxicity occurred. Transurethral resection of the prostate (TURP) was a risk factor that predicted a decline in urinary related QOL, and age made a difference to bowel-related QOL. For sexual QOL, castration status was a remarkable risk factor. An international prostate symptom score (IPSS) ≥8 increased the risk of Grade 1–2 acute GU toxicity 5.3-fold. Conclusion: Patients with prostate cancer had favorable QOL after CIRT. IPSS ≥8 was a risk factor to acute GU toxicity, and TURP predicted a decline in urinary QOL. Age was related to bowel QOL, and castration status was associated with sexual QOL. Trial registration: Carbon Ion Radiotherapy for the Treatment of Localized Prostate Cancer, NCT02739659. Registered April 15, 2016. Keywords: Prostate cancer, Carbon ion therapy, Quality of life, GU toxicity
Background Prostate cancer is the most common urologic cancer among Chinese men with largest increase in incidence of all cancers in 2015 [1]. Carbon ion radiotherapy (CIRT) have high relative biological effectiveness and a low oxygen enhancement ratio, resulting in stronger cytocidal effects * Correspondence: [email protected]; [email protected] 2 Department of Radiation Oncology, Shanghai Proton and Heavy lon Center, Shanghai 201321, China 1 Department of Radiation Oncology, Shanghai Proton and Heavy lon Center, Fudan University Cancer Hospital, No.4365 Kang Xin Road, Shanghai 201321, China Full list of author information is available at the end of the article
than conventional radiotherapy [2, 3]. Further, carbon ions offer the advantage of obvious maximum dose deposition in the deep localized region, the so-called Bragg peak, which can lead to more accurate dose concentration to the tumor, as well as reduced tox
Data Loading...
